With operations across 50 countries, MagicLab is pairing new robot systems with a platform strategy aimed at wider commercial adoption
Updated
May 1, 2026 2:16 PM
.jpg)
A standing yellow robotic arm. PHOTO: UNSPLASH
MagicLab Robotics is a Chinese startup that describes itself as an embodied AI company. At an event in Silicon Valley this week, it outlined its global ambitions and introduced new products designed for real-world use. The company said its international business now spans more than 50 countries and regions, with overseas markets accounting for 60% of total sales in 2025. That gives some indication of how quickly Chinese robotics firms are expanding beyond their home market.
At the centre of the announcement was MagicLab’s latest product line-up. It included Magic-Mix, described as a foundational world model for robots, the H01 dexterous robotic hand and its humanoid robot, MagicBot X1. In practical terms, the company is trying to build robots that can better understand their surroundings and perform physical tasks with greater precision. That is the core idea behind embodied AI, where intelligence is combined with movement and interaction in the real world rather than limited to software alone.
MagicLab says it develops both hardware and software internally. Its product range includes humanoid robots and four-legged machines, with systems designed for factories, commercial services and home use. The company also outlined where it sees demand emerging. It listed sectors such as healthcare, manufacturing, logistics, security, public safety, education and household assistance.
That wide spread of target markets reflects a broader challenge in robotics. Building capable machines is only one part of the equation. The harder task is finding enough practical uses where customers are willing to pay for them.
MagicLab also used the summit to set out a long-term commercial goal. It projected a path toward US$14 billion in annual revenue by 2036 through wider adoption of embodied AI systems. It also announced what it calls the “Co-Create 1000 Initiative”, a plan to work with external developers and partner companies.
As part of that effort, the startup said it plans to invest US$1 billion over the next five years to build a developer ecosystem that would allow third parties to create new applications for its robots. The strategy mirrors what happened in smartphones and cloud software, where ecosystems often mattered as much as the original hardware. If robotics follows a similar path, companies that attract developers could gain an advantage over those selling machines alone.
For now, MagicLab’s announcement is less about immediate breakthroughs and more about positioning. The company is presenting itself not simply as a robot maker, but as a platform business seeking a role in the next phase of intelligent machines.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.